Mar 06, 2023 / 02:50PM GMT
Philip M. Nadeau - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
Welcome to the TD Cowen 43rd Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analyst here at Cowen. It's my pleasure to moderate a fireside chat with Biogen. We're really happy to have with us today, Chris Viehbacher, the new CEO.
Chris, congratulations on assuming the role of CEO as BioCentury said this weekend, you have a tiger by the tail.
Questions and Answers:
Philip M. Nadeau - Cowen and Company, LLC, Research Division - MD & Senior Research AnalystMaybe we'll start just with a general question. What's your view of the state of Biogen now? And what do you think Biogen needs to do over the next 5 years to create shareholder value?
Christopher A. Viehbacher - Biogen Inc. - President, CEO & Director
Well, thanks, Phil. It's good to be with you this morning. Biogen is in kind of two situations. On the one hand, we have the Biogen that has been successful over 45 years in multiple